RhumbLine Advisers
KRTX

RhumbLine Advisers’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

RhumbLine Advisers’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-47,175
Closed -$14.9M – 4280
2023
Q4 		$14.9M Sell
47,175
-312
-0.7% -$60.6K 0.02% 834
2023
Q3 		$8.03M Buy
47,487
+374
+0.8% +$70.3K 0.01% 1096
2023
Q2 		$10.2M Buy
47,113
+3,155
+7% +$676K 0.01% 1000
2023
Q1 		$7.99M Buy
43,958
+1,917
+5% +$367K 0.01% 1072
2022
Q4 		$8.26M Buy
42,041
+1,928
+5% +$413K 0.01% 1030
2022
Q3 		$9.02M Buy
40,113
+9,048
+29% +$1.83M 0.01% 936
2022
Q2 		$3.93M Buy
31,065
+7,985
+35% +$918K 0.01% 1381
2022
Q1 		$2.93M Buy
23,080
+669
+3% +$75.3K ﹤0.01% 1609
2021
Q4 		$2.94M Sell
22,411
-239
-1% -$30.9K ﹤0.01% 1683
2021
Q3 		$2.77M Buy
22,650
+539
+2% +$62.2K ﹤0.01% 1710
2021
Q2 		$2.52M Buy
22,111
+3,756
+20% +$439K ﹤0.01% 1834
2021
Q1 		$2.21M Sell
18,355
-1,633
-8% -$185K ﹤0.01% 1865
2020
Q4 		$2.03M Buy
19,988
+190
+1% +$17.6K ﹤0.01% 1832
2020
Q3 		$1.53M Sell
19,798
-3,029
-13% -$258K ﹤0.01% 1819
2020
Q2 		$2.54M Buy
22,827
+8,870
+64% +$771K ﹤0.01% 1592
2020
Q1 		$1M Buy
13,957
+8,943
+178% +$765K ﹤0.01% 1878
2019
Q4 		$378K Buy
+5,014
New +$220K ﹤0.01% 2491

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

RhumbLine Advisers's KRTX Position: Q1 2024 in Review

RhumbLine Advisers sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 47,175 shares — an estimated $14.9M sold.

RhumbLine Advisers first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $14.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • RhumbLine Advisers reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 47,175 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $14.9M.
  • RhumbLine Advisers first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
  • RhumbLine Advisers's Karuna Therapeutics, Inc. Common Stock position peaked at $14.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on RhumbLine Advisers's 13F filing for Q1 2024, filed 9 May 2024.